Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraovarian PRP and rFSH injection in poor ovarian responders undergoing IVF
IRCT20091012002576N33Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of recombinant human follicle stimulating hormone and platelet-rich plasma in infertility and poor ovarian response (POR) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Number of oocytes retrieved, Chemical pregnancy outcome and 1 more. Started Sep 2023; status: completed.
02
Drugs
recombinant human follicle stimulating hormoneplatelet-rich plasma
03
Conditions
infertilitypoor ovarian response (POR)
Beyond the preview
Go deeper on IRCT20091012002576N33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091012002576N33.